Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 30 Records) |
| Query Trace: Neutropenia and GSTP1[original query] |
|---|
| Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 2004 Jan 103 (1): 67-72. Kishi Shinji, Yang Wenjian, Boureau Benoit, Morand Stanislas, Das Soma, Chen Peixian, Cook Edwin H, Rosner Gary L, Schuetz Erin, Pui Ching-Hon, Relling Mary |
| Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clinical pharmacology and therapeutics 2006 Jun 79 (6): 570-80. Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V, Dieras V, Pons G, Goldwasser F, Tréluyer J |
| A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006 Nov 1 (9): 972-8. Pillot Giancarlo A, Read William L, Hennenfent Kristin L, Marsh Sharon, Gao Feng, Viswanathan Avinash, Cummings Kristopher, McLeod Howard L, Govindan Ramaswa |
| Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. The pharmacogenomics journal 2010 Feb 10 (1): 54-61. Khrunin A V, Moisseev A, Gorbunova V, Limborska |
| Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients. Journal of human genetics 2009 Oct 54 (10): 564-71. Low Siew-Kee, Kiyotani Kazuma, Mushiroda Taisei, Daigo Yataro, Nakamura Yusuke, Zembutsu Hitos |
| Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Jun 27 (17): 2863-73. Goekkurt Eray, Al-Batran Salah-Eddin, Hartmann Jörg T, Mogck Ulrike, Schuch Gunter, Kramer Michael, Jaeger Elke, Bokemeyer Carsten, Ehninger Gerhard, Stoehlmacher J |
| Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis. Cancer chemotherapy and pharmacology 2011 Jun 67 (6): 1323-31. Hong Junshik, Han Sae-Won, Ham Hye Seon, Kim Tae-Yong, Choi In Sil, Kim Byung-Su, Oh Do-Youn, Im Seock-Ah, Kang Gyeong Hoon, Bang Yung-Jue, Kim Tae-Y |
| Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Jul 28 (20): 3227-33. McLeod Howard L, Sargent Daniel J, Marsh Sharon, Green Erin M, King Cristi R, Fuchs Charles S, Ramanathan Ramesh K, Williamson Stephen K, Findlay Brian P, Thibodeau Stephen N, Grothey Axel, Morton Roscoe F, Goldberg Richard |
| Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. British journal of cancer 2010 Mar 102 (6): 987-94. Zarate R, Rodríguez J, Bandres E, Patiño-Garcia A, Ponz-Sarvise M, Viudez A, Ramirez N, Bitarte N, Chopitea A, Gacía-Foncillas |
| Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Dec 16 (24): 6169-76. Yao Song, Barlow William E, Albain Kathy S, Choi Ji-Yeob, Zhao Hua, Livingston Robert B, Davis Warren, Rae James M, Yeh I-Tien, Hutchins Laura F, Ravdin Peter M, Martino Silvana, Lyss Alan P, Osborne C Kent, Abeloff Martin, Hortobagyi Gabriel N, Hayes Daniel F, Ambrosone Christine |
| Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer chemotherapy and pharmacology 2011 May . Joerger M, Burgers JA, Baas P, Doodeman VD, Smits PH, Jansen RS, Vainchtein LD, Rosing H, Huitema AD, Beijnen JH, Schellens JH |
| A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. The pharmacogenomics journal 2013 Oct 13 (5): 403-9. Cecchin E, D'Andrea M, Lonardi S, Zanusso C, Pella N, Errante D, De Mattia E, Polesel J, Innocenti F, Toffoli |
| Pharmacogenetic influence of GST polymorphisms on anthracycline-based chemotherapy responses and toxicity in breast cancer patients: a multi-analytical approach. Molecular diagnosis & therapy 2013 Dec 17 (6): 371-9. Tulsyan Sonam, Chaturvedi Pankaj, Agarwal Gaurav, Lal Punita, Agrawal Sushma, Mittal Rama Devi, Mittal Balr |
| Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. Cancer chemotherapy and pharmacology 2013 Jun 71 (6): 1463-72. Cortejoso Lucía, García María I, García-Alfonso Pilar, González-Haba Eva, Escolar Fernando, Sanjurjo María, López-Fernández Luis |
| Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer. Cancer chemotherapy and pharmacology 2013 Jan . Lee KH, Chang HJ, Han SW, Oh DY, Im SA, Bang YJ, Kim SY, Lee KW, Kim JH, Hong YS, Kim TW, Park YS, Kang WK, Shin SJ, Ahn JB, Kang GH, Jeong SY, Park KJ, Park JG, Kim TY |
| Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients. Scientific reports 2014 4 6828. Ruzzo Annamaria, Graziano Francesco, Galli Fabio, Giacomini Elisa, Floriani Irene, Galli Francesca, Rulli Eliana, Lonardi Sara, Ronzoni Monica, Massidda Bruno, Zagonel Vittorina, Pella Nicoletta, Mucciarini Claudia, Labianca Roberto, Ionta Maria Teresa, Veltri Enzo, Sozzi Pietro, Barni Sandro, Ricci Vincenzo, Foltran Luisa, Nicolini Mario, Biondi Edoardo, Bramati Annalisa, Turci Daniele, Lazzarelli Silvia, Verusio Claudio, Bergamo Francesca, Sobrero Alberto, Frontini Luciano, Magnani Mau |
| Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer chemotherapy and pharmacology 2015 Apr 75 (4): 763-72. Joerger M, Huitema A D R, Boot H, Cats A, Doodeman V D, Smits P H M, Vainchtein L, Rosing H, Meijerman I, Zueger M, Meulendijks D, Cerny T D, Beijnen J H, Schellens J H |
| Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy. BMC cancer 2017 Jul 17 (1): 502. Ludovini Vienna, Antognelli Cinzia, Rulli Antonio, Foglietta Jennifer, Pistola Lorenza, Eliana Rulli, Floriani Irene, Nocentini Giuseppe, Tofanetti Francesca Romana, Piattoni Simonetta, Minenza Elisa, Talesa Vincenzo Nicola, Sidoni Angelo, Tonato Maurizio, Crinò Lucio, Gori Stefan |
| Effects of gene polymorphisms on the risk of severe hyponatremia during DCF chemotherapy for patients with esophageal squamous cell carcinoma. Oncology letters 2018 Oct 16 (4): 5455-5462. Arakawa Yasuhiro, Shirai Yoshihiro, Hayashi Kazumi, Tanaka Yujiro, Matsumoto Akira, Nishikawa Katsunori, Yano Shin |
| GSTP1 rs1695 is associated with both hematological toxicity and prognosis of ovarian cancer treated with paclitaxel plus carboplatin combination chemotherapy: a comprehensive analysis using targeted resequencing of 100 pharmacogenes. Oncotarget 2018 Jul 9 (51): 29789-29800. Yoshihama Tomoko, Fukunaga Koya, Hirasawa Akira, Nomura Hiroyuki, Akahane Tomoko, Kataoka Fumio, Yamagami Wataru, Aoki Daisuke, Mushiroda Tais |
| Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy. Oncotarget 2017 Dec 8 (69): 113531-113542. van Rossum Annelot G J, Kok Marleen, McCool Danielle, Opdam Mark, Miltenburg Nienke C, Mandjes Ingrid A M, van Leeuwen-Stok Elise, Imholz Alex L T, Portielje Johanneke E A, Bos Monique M E M, van Bochove Aart, van Werkhoven Erik, Schmidt Marjanka K, Oosterkamp Hendrika M, Linn Sabine |
| Pathway genes and metabolites in thiopurine therapy in Korean children with acute lymphoblastic leukaemia. British journal of clinical pharmacology 2019 Mar . Choi Rihwa, Sohn Insuk, Kim Min-Ji, Woo Hye In, Lee Ji Won, Ma Youngeun, Yi Eun Sang, Koo Hong Hoe, Lee Soo-Yo |
| Association Study Among Candidate Genetic Polymorphisms and Chemotherapy-Related Severe Toxicity in Testicular Cancer Patients. Frontiers in pharmacology 2019 10 206. Lavanderos María A, Cayún Juan P, Roco Ángela, Sandoval Christopher, Cerpa Leslie, Rubilar Juan C, Cerro Roberto, Molina-Mellico Sebastián, Celedón Cesar, Cerda Berta, García-Martín Elena, Agúndez José A G, Acevedo Cristián, Peña Karina, Cáceres Dante D, Varela Nelson M, Quiñones Luis |
| Genetic polymorphisms of GSTP1, XRCC1, XPC and ERCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer patients of Bangladesh. Molecular biology reports 2020 Sep . Bushra Most Umme, Rivu Sanzana Fareen, Sifat Ali Ehsan, Nahid Noor Ahmed, Ahmed Maizbha Uddin, Al-Mamun Mir Md Abdullah, Apu Mohd Nazmul Hasan, Islam Md Siddiqul, Islam Md Reazul, Islam Mohammad Safiqul, Hasnat Ab |
| Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance). Pharmacogenetics and genomics 2021 Jun . Patel Jai N, Jiang Chen, Owzar Kouros, Mulkey Flora, Luzum Jasmine A, Mamon Harvey J, Haller Daniel G, Dragovich Tomislav, Alberts Steven R, Bjarnason Georg, Willet Christopher G, Niedzwiecki Donna, Enzinger Peter, Ratain Mark J, Fuchs Charles, McLeod Howard |
| GSTP1 IleVal polymorphism among North Indian lung cancer patients treated using monotherapy and poly-pharmacy. Human & experimental toxicology 2021 Nov 9603271211059496. Walia Harleen Kaur, Singh Navneet, Sharma Siddhar |
| GSTP1 c.313A?>?G mutation is an independent risk factor for neutropenia hematotoxicity induced by anthracycline-/paclitaxel-based chemotherapy in breast cancer patients. World journal of surgical oncology 2022 Jun 20 (1): 212. Zeng Juanzi, Wu Heming, Liu Donghua, Li Liang, Li Jiaquan, Wang Qiuming, Ye Min, Huang Qingyan, Yu Zhikang, Zhang Jinfe |
| Association between Genetic Polymorphism of GSTP1 and Toxicities in Patients Receiving Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis. Pharmaceuticals (Basel, Switzerland) 2022 4 15 (4): . Kim Woorim, Cho Young-Ah, Kim Dong-Chul, Lee Kyung-E |
| The Relation of Haplotype ATP-binding Cassette B1 and Glutathione S-transferase P1 A313G Genes with Hematological Toxicity in Indonesian Breast Cancer Patients Receiving Chemotherapy. Oman medical journal 2022 4 37 (2): e357. Syarifah Siti, Widyawati Tri, Hasni Dita, Sari Mutiara Indah, Rusdiana Rusdiana, Hamdi Tasr |
| Gene polymorphism and prediction of toxicity to platinum-based chemotherapy in patients with gynecologic cancer. Clinical and translational science 2023 11 . Xuan Huang, Junmin Li, Xiaoying Pang, Jialei Zhu, Jiaqian Pan, Yueyan Li, Jing Ta |
- Page last reviewed:Oct 1, 2023
- Page last updated:Dec 04, 2023
- Content source: